Along the line of searching for biomarkers of prediction and revealing the molecular mechanism of progestin resistance, we recently came across the findings that Nrf2 and AKR1C1 were overexpressed only in partially responding and non-responding endometrial cancer samples after progestin treatment. The gene discussed is NFE2L2; the disease is endometrial cancer.